Unknown PHASE2 INTERVENTIONAL 5-arm NCT01489228

Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease

Phase 2 Randomized, Multicenter, Placebo-controlled, Safety and Efficacy Study to Evaluate Three Oral E1224 Dosing Regimens and Benznidazole for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease

Sponsor: Drugs for Neglected Diseases

Conditions Chronic Chagas Disease, Indeterminate

Interventions Benznidazole E1224 Placebo

Updated 6 times since 2017 Last updated: Dec 19, 2011 Started: Jun 30, 2011 Primary completion: Aug 31, 2012 Completion: Dec 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Chronic Chagas Disease, Indeterminate, this trial is ongoing. The trial is conducted by Drugs for Neglected Diseases and has accumulated 6 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE2

First recorded

Jun 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Drugs for Neglected Diseases
Eisai Co., Ltd.

Data source: Drugs for Neglected Diseases

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cochabamba, Bolivia
• Tarija, Bolivia